Voltar
Artigo Acesso aberto Revisado por pares
BIBTEX RIS

Budesonide induction and maintenance therapy for Crohnʼs disease during pregnancy

2008; Oxford University Press; Volume: 15; Issue: 1 Linguagem: Inglês

10.1002/ibd.20640

ISSN

1536-4844

Autores

Dawn B. Beaulieu, Ashwin N. Ananthakrishnan, Mazen Issa, Lydia Rosenbaum, Sue Skaros, Julianne Newcomer, Randall S. Kuhlmann, Mary F. Otterson, Jeanne Emmons, Josh F. Knox, David G. Binion,

Tópico(s)

Microscopic Colitis

Resumo

BackgroundThere is no standard approach for the medical management of Crohn's disease (CD) during pregnancy and there is limited data regarding safety and efficacy of the treatments. Budesonide (Entocort® EC, AstraZeneca) is an enteric coated locally acting glucocorticoid preparation whose pH- and time-dependent coating enables its release into the ileum and ascending colon for the treatment of mild to moderate Crohn's disease. There is no available data on the safety of using oral budesonide in pregnant patients.

Referência(s)